Well I see we've got news today...
Advanced Optics Electronics Inc. BioModa Holding
Announces Technology Tested For Commercial Use
In Foreign Markets
ALBUQUERQUE, N.M.
(BUSINESS WIRE) - Feb.
16, 1999-BioModa Inc,
announced on Feb. 8 it is now prepared to begin "Opinion
Leader" testing of its TCPP Diagnostic for abnormal lung
cells. BioModa's tests will be conducted in cooperation
with foreign partners in Korea, China, India, Australia and
Romania.
"Commercial use of clinical tests in these countries
represents a significant milestone reached by our
research staff," stated BioModa's President, Ari Ma'ayan.
"We have successfully developed strong partner
relationships in Korea, China, India, Australia and
Romania.
"These potential markets include more than two billion
people and over $500 million in estimated revenues for
lung cancer testing over the next 3 years."
"From a humanitarian standpoint, lung cancer has
reached epidemic proportions in these countries and,
consequently, we are able to obtain unprecedented
access through government officials. In China alone, more
than one million people die of lung cancer annually, and
that number continues to rise dramatically."
The BioModa TCPP diagnostic can detect pre-cancerous
changes in the cells lining a person's lungs several years
prior to the onset of invasive carcinoma. "Obviously,
earlier detection is the focus of our technology," said Jeff
Garwin, MD, PhD, BioModa's chief technical officer. "We
believe our test will provide the means for saving millions
of lives worldwide."
The test materials are currently available in the US in a
"bulk" format and will soon be available in a "kit" format.
Upon completion of the test kit and commercial
distribution of same, the company plans to follow up the
TCPP lung test with additional diagnostics related to
cancer in other organs of the body.
In addition to their patented lung cancer test, BioModa is
working on diagnostic imaging and radio pharmaceutical
therapeutic for lung cancer and other cancers.
About the Company
BioModa Inc. is an emerging biomedical company
specializing in breakthrough cancer diagnostics and
therapy.
BioModa Inc. owns a patented lung cancer test capable of
detecting lung cancer up to six years earlier than any other
available test and recently received efficacy confirmation
from double-blind studies conducted by LungCheck(R) Inc.
of Scottsdale, AZ.
BioModa's technology also encompasses the treatment of
lung cancer. BioModa's prominent research team has
included world-leading cytopathologists, Dr. Geno
Saccomanno of St. Mary's Hospital and Medical Center,
Dr. Jim Mulshine of the National Cancer Institute and the
late Dr. John Frost of Johns Hopkins University.
Also currently involved in BioModa's research is Dr. L.
Edward Ellinwood, a nationally recognized
pharmacologist from St. Mary's Hospital and Los Alamos
National Laboratories.
BioModa Inc. has conducted the bulk of its research
through grants, private and public investments and through
an equity investment from Advanced Optics Electronics
Inc.(OTC BB:ADOT). BioModa is currently negotiating
major financing with several of the largest investment
banking firms in the country.
Advanced Optics Electronics Inc. currently owns 22.8
percent of BioModa Inc. with an option, if fully exercised
which allows Advanced Optics Electronics Inc. position to
move to approximately 26.5 percent of BioModa Inc.
Advanced Optics Company Information
Advanced Optics Electronics Inc. (OTC BB:ADOT) is a
developer of patented electronic display technology,
utilizing ADOT's proprietary SLM (Spatial Light Modulator)
light valve.
This industry-leading technology can be utilized in many
diverse fields including the production of "television
quality" advertising billboards, medical testing equipment,
military displays, computer monitors and high definition
video transmission.
Shareholder Relations Note
ADOT will promptly respond to all requests for information
from shareholders and the general public, shareholders
will receive priority response. All such requests must be
sent to ADOT via FAX: 505/858-1871 or U.S. Mail to
8301 Washington Ave. Building 4, Albuquerque, NM
87113.
All such requests must include the Name, Daytime Fax (if
available) and Street Address as box numbers cannot be
accepted.
This News Release contains forward-looking statements
with respect to the results of operations and business of
the company that involves risk and uncertainties. The
company's actual future results could materially differ from
those discussed.
Risks and uncertainties of the company will be detailed
from time to time in the company's periodic reports to be
filed with the Securities and Exchange Commission.
Contact Advanced Optics Electronics Inc. at
505/797-7878 or visit their Web site at www.adot.org.
|
